B
PASG icon

Bailard’s Passage Bio PASG Stock Holding History

Bailard’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,845
Closed -$217K – 768
2022
Q4 		$217K Buy
+7,845
New +$198K 0.01% 632

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Bailard's PASG Position: Q1 2023 in Review

Bailard sold out of Passage Bio (PASG) in Q1 2023, closing a stake of 7,845 shares — an estimated $217K sold.

Bailard first reported a position in PASG in Q4 2022 and held it in 1 quarter. The position peaked at $217K in Q4 2022. 58 funds tracked by Wall St. Rank hold PASG as of Q1 2023.

  • Bailard reported no remaining Passage Bio position as of Q1 2023 after selling out during the quarter.
  • Bailard sold 7,845 Passage Bio shares in Q1 2023, an estimated $217K.
  • Bailard first reported a position in Passage Bio in Q4 2022 and held it in 1 quarter.
  • Bailard's Passage Bio position peaked at $217K in Q4 2022.
  • 58 funds tracked by Wall St. Rank held Passage Bio as of Q1 2023.

Based on Bailard's 13F filing for Q1 2023, filed 8 May 2023.